Barber Daniel 4

4 · Aquestive Therapeutics, Inc. · Filed Mar 11, 2026

AI-generated summary of this filing

Updated Mar 11, 2026

Aquestive (AQST) CEO Daniel Barber Sells Shares

What Happened

Daniel Barber, President and CEO of Aquestive Therapeutics (AQST), sold 180,677 shares in an open-market transaction on March 10, 2026 for total proceeds of $753,965 (weighted-average price $4.17). On March 9, 2026 he also received (a) 262,000 restricted shares (reported at $0) and (b) a derivative award covering 523,000 shares with a reported value of $4.29 per share (total $2,243,670). The sale was a routine “sell to cover” tied to tax withholding for vested awards, not a discretionary trade.

Key Details

Transaction dates and prices:
- Mar 9, 2026: Award of 262,000 restricted shares (reported $0) and derivative award for 523,000 shares at $4.29 ($2,243,670).
- Mar 10, 2026: Open-market sale of 180,677 shares; weighted-average sale price $4.17 (individual trades ranged $4.17–$4.33).
Shares owned after transaction: Not specified in the reported data on this filing.
Notable footnotes:
- F1/F4: Restricted stock and the options/derivative award vest in three annual installments (25% / 25% / 50%).
- F2: The sale represents shares sold to satisfy tax-withholding obligations (a mandatory "sell to cover"), not a discretionary sale by the insider.
- F3: Sale executed in multiple trades; weighted-average price reported.
Filing timeliness: Form 4 was filed Mar 11, 2026 for transactions on Mar 9–10, 2026 (appears to be filed within the standard 2-business-day window).

Context

The derivative award appears to be stock options or similar equity awards that vest over time; these are not immediate purchases of common stock and typically become meaningful only as they vest/exercised. The share sale was tied to tax withholding for vested awards (routine) rather than an independent investment decision.

Form 4

Period: 2026-03-09

President and CEO

Transactions

Award
Common Stock
[F1]
2026-03-09+262,000→ 1,185,430 total
Sale
Common Stock
[F2][F3]
2026-03-10$4.17/sh−180,677$753,965→ 1,004,753 total
Award
Non-Qualified Stock Option (right to buy)
[F4]
2026-03-09$4.29/sh+523,000$2,243,670→ 523,000 total
Exercise: $4.29Exp: 2036-03-09→ Common Stock (523,000 underlying)

Footnotes (4)

[F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
[F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
[F3]This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Signature

/s/ Lori Braender, as Attorney-In-Fact|2026-03-11

1 file